Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy

Pharmacogenetics and Genomics

Volumn 19, Issue 12, 2009, Pages 955-964

  Ishido, Kenji ^a   Azuma, Mizutomo ^a   Koizumi, Wasaburo ^a   Takeuchi, Atsuko ^a   Sakuramoto, Shinichi ^a   Watanabe, Masahiko ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Advanced gastric cancer; S 1; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GASTRECTOMY; GENE EXPRESSION; HUMAN; LASER CAPTURE MICRODISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BIOMARKERS, PHARMACOLOGICAL; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PILOT PROJECTS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; THYMIDYLATE SYNTHASE;

EID: 73949130655     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328333351b     Document Type: Article

References (31)

1. Diasio RB, Johnson MR. The role of pharmacogenetics and pharma-cogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61:199-203.
2. Danenberg PV. Thymidylate synthase-a target enzyme in cancer chemotherapy. Biochim Biophys Acta 1977; 473:73-92.
3. Hamaguchi T. Pharmacogenomics of 5-FU-based chemotherapy. Pharmacogenom Cancer Ther 2007; 5:136-140.
4. Leichman CG, Lenz HJ, Leichman L, Darnenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-3229.
5. Iba T, Yagi Y, Kidokoro A, Ishi K, Koyatsu J. The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer. Gan To Kagaku Ryoho 1998; 25:1165-1171.
6. Ichikawa W, Uetake H, Kirihara M, Yamada H, Shirota Y, Tajima M, et al. Tumor tailored chemotherapy for colorectal cancer in terms of thymidylate synthase and dihydropyrimidine dehydrogenase. J Jpn Soc Colo-proctol 2000; 53:1023-1028.
7. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-557.
8. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58:191-197.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 mol/l tegafur-0.4 mol/l gimestat-1 mol/l otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
10. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999; 57:202-210.
11. Boku N, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Chemotherapy for metastatic disease: review from JCOG trials. Int J Clin Oncol 2008; 13:196-200.
12. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215-221.
13. Sakuramoto S, Sasako M, Yamaguchi T, Fujii M, Nashimoto A, Furukawa H, et al., ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 1810-1820.
14. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14:176-182.
15. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
16. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
17. Maehara Y, Kusumoto T, Kusumoto H, Anai H, Sakaguchi Y, Kido Y, et al. 5-Fluorouracil and UFT-sensitive gastric carcinoma has high level of thymidylate synthase. Cancer 1989; 63:1693-1696.
18. Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T, Sakaue M, et al. Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 1992; 70:2761-2765.
19. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and-resistant human cancer cell lines. Cancer Res 1992; 52:4306-4312.
20. Yoshida T, Shimooki O, Baba Y, Abe T, Sugai T, Nakamura S. Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma. Gan To Kagaku Ryoho 2005; 32:183-187.
21. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-1412.
22. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-316.
23. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, et al. Thymidylate synthase predictive power is outcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004; 91:1245-1250.
24. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 2006; 9:145-155.
25. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant treated gastric cancer patients. Clin Cancer Res 2005; 11:3025-3031.
26. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, et al. Thymidylate synthase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res 2004; 24:2455-2463.
27. Hua D, Huang ZH, Mao Y, Deng JZ. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 2007; 13:5030-5034.
28. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 1999; 19:5635-5640.
29. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, et al. Simple combination of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006; 119:1927-1933.
30. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, Fukushima M. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol 2000; 17:653-658.
31. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20.